3 results
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Not approvedWill not start
The purpose of this study is to evaluate whether there are differences in duration and intensity at a femoral nerve block with ropivacaine Klaris standard 30ml 0.2% with and without addition of buprenorphine (Temgesic ®) 0.3 mg buprenorphine…
Approved WMOPending
Main objective Monotherapy Cohorts (R/R CLL):• Identify the RP2D and the MTD of epcoritamab• Evaluate the safety and tolerability of epcoritamabExpansion Monotherapy (R/R CLL [Arm 1] and RS [Arm 2A]):• Assess the preliminary efficacy of…